Anthracycline cardiomyopathy


Cite item

Full Text

Abstract

Anthracycline antibiotics are highly effective in the treatment of cancer, but their cardiotoxicity limits use of these antibiotics. A cardiotoxic action of anthracyclines provokes development of dilated cardiomyopathy with or without symptoms of cardiac insufficiency (CI). Anthracyclines have a long-term cardiotoxic action, therefore, with time, the rate of cardiomyopathy development increases. Follow-up echocardiography is an optimal method for assessment of cardiac function. Such parameters as left ventricular ejection fraction and the degree of the anteroposterior shortening are most essential. Cardiac failure symptoms are managed in the same way as in other pathology.

About the authors

Vasiliy Nefedovich Anokhin

Email: n.engelbert@mail.ru

Mikhail Ivanovich Chushkin

Email: mchushkin@yandex.ru

Aleksandr Viktorovich Kolganov

Email: kolganov-hem@yandex.ru

V N Anokhin

Medical Center of Russian Bank

Medical Center of Russian Bank

M I Chushkin

Medical Center of Russian Bank

Medical Center of Russian Bank

A V Kolganov

Medical Center of Russian Bank

Medical Center of Russian Bank

References

  1. Окороков А. Н. Диагностика болезней внутренних органов: Т. 8: Диагностика болезней сердца и сосудов. М.: Мед. лит.; 2004.
  2. Личиницер М. Р., Вышинская Г. В., Миников Е. Д. и др. Применение кардиоксана в качестве кардиопротективного средства при противоопухолевой химиотерапии. Тер. арх. 1994; 7: 54-56.
  3. Carver J. R., Shapiro C. L., Ng A. et al. For the ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology. Clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. J. Clin. Oncol. 2007; 25: 3991-4008.
  4. Shankar S. M., Marina N., Hudson M. M. et al. Monitoring for cardiovascular disease in survivors of childhood cancer: Report from the cardiovascular disease task force of the children's oncology group. Pediatrics 2008; 121: e387-e396.
  5. Pai V. B., Nahata M. C. Cardiotoxicity of chemotherapeutic agents. Drug Safety 2000; 22(4): 263-302.
  6. Singal P. K., Iliskovic N., Li T., Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 1997; 11: 931-936.
  7. Shan K., Lincoff A. M., Young J. B. Anthracycline-induced cardiotoxicity. Ann. Intern. Med. 1996; 125(1): 47-58.
  8. Billingham M. E., Mason J. W., Bristow M. R., Daniels J. R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. 1978; 62: 865-875.
  9. Калинкина H. B. Повреждение сердца антрациклинами: частота и факторы риска. Укр. мед. журн. 2000; 2: 25-29.
  10. Minotti G., Menna Р., Salvatorelli E. et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56: 185-229.
  11. Brislow M. R., Billingham M. E., Mason J. W., Daniels J. R. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat. Rep. 1978; 62: 873-879.
  12. Saltiel E., McGuire W. Doxorubicin (Adriamycin) Cardiomyopathy. A critical review. West. J. Med. 1983; 139: 332-341.
  13. Von Hoff D. D., Layard M. W., Basa Р. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 1979; 91: 710-717.
  14. Steinherz L. J., Steinherz P. G., Tan C. T. et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J. A. M. A. 1991; 266(12): 1672-1677.
  15. Lipshultz S. E., Colan S. D., Gelber R. D. et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 1991; 324(12): 808-815.
  16. Jensen B. V., Skovsgaard T., Nielsen L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann. Oncol. 2002; 13: 699-709.
  17. Cooper L. T., Baughman K. L., Feldman A. M. et al. American Heart Association; American College of Cardiology; European Society of Cardiology; Heart Failure Society of America; Heart Failure Association of the European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur. Heart J. 2007; 28(24): 3076-3079.
  18. Mason J. W., Bristow M. R., Billingham M. E., Daniels J. R. Invasive and noninvasive methods of assessing Adriamycin cardiotoxic effects in man: Superiority of histiopathologic assessment using endomyocardial biopsy. Cancer Treat. Rep. 1978; 62: 857-864.
  19. Singal P. K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 1998; 339(13): 900-905.
  20. Jannazzo A., Hoffman J., Lutz M. Monitoring of Anthracycline-induced cardiotoxicity. Ann. Pharmacother. 2008; 42: 99-104.
  21. Steinherz L. J., Graham T., Hurwitz R. et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992; 89: 942-949.
  22. Van Dalen E. C., van den Brug M., Caron H. N., Kremer L. C. Anthracycline-induced cardiotoxicity: Comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur. J. Cancer. 2006; 42: 3199- 3205.
  23. Schwartz R. G., McKenzie W. B., Alexander J. et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am. J. Med. 1987; 82: 1109-1118.
  24. Gianni L., Herman E. H., Lipshultz S. E. et al. Anthracycline cardiotoxicity: From bench to bedside. J. Clin. Oncol. 2008; 26(22): 3777-3784.
  25. Lipshultz S. E., Sanders S. P., Goorin A. M. et al. Monitoring for anthracycline cardiotoxicity. Pediatrics 1994; 93(3): 433-437.
  26. Ewer M. S., Lenihan D. J. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J. Clin. Oncol. 2008; 26(8): 1201-1203.
  27. De Caro E., Fioredda F., Calevo М. G. et al. Exercise capacity in apparently healthy survivors of cancer. Arch. Dis. Child. 2006; 91: 47-51.
  28. Hauser M., Gibson B. S., Wilson N. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography. Eur. J. Pediatr. 2001; 160: 607-610.
  29. Carver J. R., Ng A., Meadows A. T., Vaughn D. J. Cardiovascular late effects and ongoing care of adult cancer survivors. Dis. Manag. 2008; 11(1): 1-6.
  30. Legha S. S., Benjamin R. S., Mackay B. et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. 1982; 96: 133-139.
  31. Safra T. Cardiac safety of liposomal anthracyclines. Oncolgist 2003; 8: 17-24.
  32. Theodoulou M., Hudis C. Cardiac profiles of liposomal anthracyclines. Cancer 2004; 100(10): 2052-2063.
  33. Wouters K. A., Kremer L. C., Miller T. L. et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. 2005, 131(5): 561-578.
  34. Barry E., Alvarez J. A., Scully R. E. et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin. Pharmacother, 2007; 8(8): 1039- 1058.
  35. Schuchter L. M., Hensley M. L., Meropol N. J., Winer E. P. American Society of Clinical Oncology Chemotheapy and Radiotherapy Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Опсоlogy 2002; 20(12): 2895-2903.
  36. Yeh E. T., Bickford C. L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 2009; 53: 2231-2247.
  37. Cardinale D., Colombo A., Sandri M. T. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474-2481.
  38. Cardinale D., Colombo A., Lamantia G. et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol. 2010; 55: 213- 220.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies